MedicaidPrior AuthMedium impact
Uplizna® (inebilizumab-cdon) (New)
Humana·IN · Neurology, Rheumatology, Internal Medicine·Medicaid
Effective date
Jun 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Indiana has established a new prior authorization policy for Uplizna® (inebilizumab-cdon) effective June 1, 2026. This specialty medication requires prior approval for four specific conditions: neuromyelitis optica spectrum disorder (NMOSD), IgG4-related disease, and two types of generalized myasthenia gravis, each with detailed clinical criteria and prior therapy requirements.
Action Required
Before June 1, 2026: Clinical staff must implement prior authorization requirements for Uplizna® (inebilizumab-cdon) for Indiana Medicaid patients. Providers treating NMOSD, IgG4-related disease, or generalized myasthenia gravis must verify patients meet specific clinical criteria including required antibody testing and prior therapy failures before prescribing. Update prior authorization checklists to include the detailed criteria for each indication. Claims will be denied without proper prior authorization.